• News
  • SAN DIEGO
  • BioTech

Isis could gain $2 billion advantage from heart attack study

Isis Pharmaceuticals Inc., a Carlsbad-based maker of gene therapy treatments, may seek to expand use of an experimental drug targeting triglycerides to fight heart disease, a move an analyst says could add $2 billion in sales.

To continue reading, subscribe now
or
log in to your account
User Response
0 UserComments

Isis Pharmaceuticals Inc.

Company Website

1896 Rutherford Road
Carlsbad, CA 92008

Company Trade Data

Stock Symbol Close
Change
Chg %Chg
Volume
52-Week
High Low
ISIS
63.37
  2.22  
+ 3.63%
4,333,877,000
77.80
22.25

Insider Trade Data

Date Insider Shares Type Value
03/24/2015 Bennett, C Frank 15,000 Sell $1,059,110
03/24/2015 Bennett, C Frank 15,000 Exchange $217,050
03/05/2015 Geary, Richard S 18,095 Sell $1,287,383
03/05/2015 Geary, Richard S 18,095 Sell $1,287,383
03/05/2015 Geary, Richard S 15,080 Exchange $133,972

Isis Pharmaceuticals Inc. Executive(s):

Stanley Crooke

  • Chief Executive Officer, Founder, President, Chairman

Similar Companies

NAICS - 325414 - Biological Product (except Diagnostic) Manufacturing
SIC - 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES
Subscribe Today!